Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab (CIM331)" Global Phase II Study Data Published in The New England Journal of Medicine Online
Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the data
from the global phase II study (the XCIMA study) for the planned
indication of atopic dermatitis (AD) was published in The New England
Journal of Medicine Online on March 2, 2017 (EST). The study was
conducted to evaluate the safety and efficacy of nemolizumab in 264
patients with moderate-to-severe AD, and the safety and efficacy of
nemolizumab at 12 weeks were confirmed.
“Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.,” Thomas Ruzicka, M.D., et al
The efficacy and safety data obtained from a one-year extension of the study will be presented on March 4th at the Late-Breaking Research Forums of the 2017 Annual American Academy of Dermatology (AAD) Meeting which will be held on March 3 to 7 in Orlando, Florida, USA.
“Control of pruritus is crucial for AD patients. It is directly related to their quality of life,” said Dr. Yasushi Ito, Senior Vice President, Head of Project & Lifecycle Management Unit. “This data emphasizes the importance of controlling IL-31 in AD. It also indicates that nemolizumab, an anti-IL-31 antibody, may offer a promising treatment option for the disease. Chugai will closely work together with its partners - Galderma and Maruho, toward helping AD patients by offering this new treatment option as early as possible.”
“Nemolizumab is the first drug specifically targeting pruritus. Its use is very convenient to patients with one subcutaneous injection per month,” said, Professor Thomas Ruzicka, Ludwig-Maximilian University Munich, the first author of the article. “Since IL-31 is involved in a variety of other pruritic skin diseases, the innovative drug has a large potential in dermatology.”
Chugai granted the exclusive development and marketing rights of
nemolizumab worldwide, excluding Japan and Taiwan to Galderma and
licensed out the development and marketing rights in the skin disease
area to Maruho for the Japanese market respectively.
Please refer to the press release for the details of the license agreement with
[Overview of the study]
264 patients were randomized to one of the four nemolizumab dose groups (0.1, 0.5, 2.0 mg/kg every 4 week (Q4W) or 2.0 mg/kg every 8 week) or placebo group (Q4W) in the ratio of 1:1:1:1:1. The primary endpoint of the study showed significant improvement of the change in pruritus VAS at 12 weeks compared with placebo with the score of -43.7% for nemolizumab 0.1 mg/kg Q4W, -59.8% for nemolizumab 0.5 mg/kg Q4W, -63.1% for nemolizumab 2.0 mg/kg Q4W and -20.9% for placebo Q4W (p<0.01 for all comparisons). The secondary endpoint was the change in EASI at week 12 of −23.0%, −42.3%, and −40.9% for the nemolizumab 0.1, 0.5 and 2.0 mg/kg Q4W groups, respectively, versus −26.6% for placebo. Another secondary endpoint, the proportion (%) of patients with ≥2-point improvement in sIGA of was 13.8%, 37.5%, 25.1% for the nemolizumab 0.1, 0.5 and 2.0 mg/kg Q4W groups, respectively, compared with 10.5% for placebo.
The most common adverse events (AEs) were the exacerbation of AD, nasopharyngitis, upper respiratory tract infections, peripheral edema, and increased creatine phosphokinase. 15 patients experienced AEs related discontinuations and 10 out of 15 were due to AEs related to AD (such as exacerbation of AD and dermatitis exfoliativa).
About nemolizumab (CIM331)
A humanized anti-human IL-31 receptor A (IL-31RA) monoclonal antibody. IL-31 is identified as a cytokine that can induce pruritus, and reported to be associated with pruritus in atopic dermatitis and dialysis patients. Nemolizumab works by inhibiting biological activity of IL-31 through competitively blocking the binding of IL-31 to its receptor.
About pruritus VAS
Pruritus VAS stands for pruritus visual analogue scale, by which the severity of pruritus is measured with a 10 cm scale on which patients draw a line to express their assessment of severity (0: no itch, 10: worst imaginable itch).
EASI (Eczema Area and Severity Index) is a tool to demonstrate severity of dermatitis with score from 0 to 72.
sIGA (static Investigator’s Global Assessment) is a tool to evaluate overall severity of dermatitis with a six-level scale from 0 to 5 (0: clear, 5: very severe).
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Disaronno: The Mixing Star Makes a Step Change and Looks to Innovation16.1.2018 16:06 | Pressemelding
After 10 years of competitions involving bartenders from different countries who were challenged to showcase the mixability of Disaronno, Disaronno’s contest The Mixing Star has changed direction. Convinced that trends today move on channels other than a performance in front of a jury, Disaronno, the most consumed Italian liqueur in the world and the brand embodying the coolest soul of Made in Italy, has transformed The Mixing Star to Innovation Hunter, a social media based "exploration" with a mission: identifying innovative trends in mixology and movers and shakers in the field, in the UK and around the world, filming and sharing them with the community of bartending experts. In London, Milan and Amsterdam Disaronno has selected a few bartenders who are revolutionizing the field. The ways in which they express innovation have been collected in a set of stylish short movies specially made by Disaronno. The protagonists are available on The Mixing Star Facebook page and YouTube channel
Christie’s Announces Public Preview Tour Dates for The Collection of Peggy and David Rockefeller16.1.2018 15:54 | Pressemelding
Christie’s is pleased to confirm additional dates and locations for public preview exhibitions of the Collection of Peggy and David Rockefeller. Following the unveiling of early highlights in Hong Kong last November, Christie’s will now tour property to its flagship galleries in London (February 21 – March 8), Beijing (April 6 - 7), Los Angeles (April 6 – 12), and Shanghai (April 10 - 11), leading up to the auctions at Christie’s Rockefeller Center in New York in late spring. With each stop on the pre-sale tour, additional works of art and objects will be unveiled, revealing new facets of this storied, multi-category collection. The exhibitions, which are open to the public, are sponsored in partnership with private aviation company VistaJet. As a guide for collectors, Christie’s has launched a special issue of Christie’s Magazine dedicated to the Collection of Peggy and David Rockefeller. The issue re-acquaints readers with the Rockefeller family’s unique place in American history, an
Continuum Accelerates Global Expansion with Portland Europe16.1.2018 15:00 | Pressemelding
Continuum ®, the exclusive provider of the only vertically integrated IT service delivery platform that enables MSPs to scale rapidly and profitably, today announced that it has signed a distribution agreement with Portland Europe, a leading distributor of scalable software solutions for the reseller channel throughout the Benelux region. The partnership will provide Portland Europe’s wide network of managed solution providers (MSPs) in the Benelux region with access to Continuum’s fully-managed remote monitoring and management (RMM) platform, powered by the company’s network operations center (NOC). Continuum’s platform has been proven to enable MSPs to efficiently manage thousands of customer endpoints, giving them back the resources to focus on higher-end, more profitable tasks at a time when skilled IT workers are highly sought-after. As opposed to having to correspond with multiple vendors, Portland Europe customers will benefit from having Continuum serve as a single point of con
ACAMS Reaches New Milestone — 60,000 Members16.1.2018 14:30 | Pressemelding
The Association of Certified Anti-Money Laundering Specialists (ACAMS) — the largest Anti-Money Laundering (AML) and financial crime prevention organization for financial crime prevention professionals — has reached a record 60,000 members worldwide. “Reaching the 60,000 membership milestone is a testament to the dedication and commitment of our members in striving for continuous learning and career advancement,” said Tim McClinton, president and managing director at ACAMS. “Our priority for the coming year is to continue the momentum by expanding our product suite in an effort to provide current, impactful and relevant training in the field of AML and financial crime prevention.” Based in Miami, Fla., and with offices throughout the world, ACAMS offers the CAMS certification training and exam in 11 languages and hosts localized chapter events in 29 countries. ACAMS has gained significant traction with its CAMS certification in fast-growing regions like Asia and the Middle East. Hue Da
Andersen Global Continues Expansion in Dubai with GN Global Consulting16.1.2018 14:30 | Pressemelding
Andersen Global is pleased to announce an added presence in Dubai via a Collaboration Agreement with GN Global Consulting, a tax firm led by Partner Abdul Wahid Nagda. GN Global Consulting is an affiliate of Griffin Nagda, one of the oldest independent accounting firms in Dubai. The collaboration with GN Global Consulting demonstrates Andersen’s larger expansion strategy in the Middle East. Abdul Wahid Nagda commented, “We have built our reputation based on quality, integrity, and providing superior services, and we look forward to working with a firm that shares these same values. The collaboration with Andersen Global will help us develop better solutions and provide even more outstanding cross-border services to our clientele.” GN Global Consulting provides a range of tax services to both businesses and individuals within the United Arab Emirates and across the globe. The firm specializes in strategic tax planning, international tax consulting, U.S. tax consulting and filing, and es
Led by Oncology Sector, Life Sciences Deal Market Value Increases in 2017 Despite Downward Trend in Deal Volume16.1.2018 14:24 | Pressemelding
Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation, has revealed that the market value of the most innovative and impactful global life sciences transactions of 2017 increased by 6% totaling US $364 billion, despite a decrease in overall deal volume. The transactions nominated for the annual Clarivate Cortellis Deal of the Year Awards include licensing and mergers and acquisitions. The announcement of the nominees at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco coincided with the Clarivate Deals and Portfolio Annual Review presentation – the foremost independent analysis of the economic trends shaping the life sciences sector in 2017. Clarivate’s Deals and Portfolio Annual Review showcased a deep-dive analysis of 4,234 life sciences transactions. While overall the aggregate dollar value for deals increased from 2016, deal volume dropped by approximately 3% and saw contractions in almost every typ
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom